Latest Conference Articles

ESMO 2021: Oncology Experts Share Game-Changing Data in Breast Cancer, Gynecologic Malignancies

September 16th 2021, 1:18pm

ESMO Congress

The 2021 ESMO Congress, held as a virtual format for the second consecutive year, is fast approaching and isn’t holding back in terms of pivotal data across malignancies, especially in breast cancer and gynecologic cancers.

CDK Inhibition May Overcome Mechanisms of Olaparib Resistance in Prostate Cancer

September 15th 2021, 5:00pm

American Urological Association Annual Meeting

By studying olaparib-sensitive and -resistant cell lines, researchers were able to gather insights regarding PARP inhibitor treatment and resistance mechanisms, including the use of CDK inhibition as a potential means of overcoming PARP inhibitor resistance in prostate cancer.

Olaparib Maintains Benefit Over Enzalutamide or Abiraterone in mCRPC

September 14th 2021, 8:50pm

American Urological Association Annual Meeting

Olaparib was still found to produce greater clinical benefit than enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer when the novel hormonal agents were examined separately rather than combined.

Clinical Response to Sotorasib May Vary By Genomic Profile in NSCLC

September 14th 2021, 6:44pm

IASLC World Conference on Lung Cancer

The clinical response to sotorasib could vary in patients with KRAS G12C–mutated non–small cell lung cancer depending on their co-mutational status.

LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach

September 14th 2021, 12:24pm

American Urological Association Annual Meeting

Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.

Dr. Choueiri on the Results of the KEYNOTE-564 Study in RCC

September 13th 2021, 9:07pm

American Urological Association Annual Meeting

Toni K. Choueiri, MD, discusses the results of the KEYNOTE-564 study in renal cell carcinoma.

Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CIS

September 13th 2021, 9:00pm

American Urological Association Annual Meeting

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

Dr. Shore on the Results of the ENACT Trial in Prostate Cancer

September 13th 2021, 8:36pm

American Urological Association Annual Meeting

Neal D. Shore, MD, FACS, discusses the results of the randomized, open label, phase 2 ENACT trial in prostate cancer.

UGN-101 Induction Produces Durable Responses in Low-Grade Upper Tract Urothelial Carcinoma

September 13th 2021, 8:05pm

American Urological Association Annual Meeting

Treatment with the mitomycin-containing reverse thermal gel UGN-101 resulted in a lengthy period of durable response when administered as induction treatment in patients with low-grade upper tract urothelial carcinoma.

Novel Neoadjuvant Triplet Shows Preliminary Promise in Resectable Pleural Mesothelioma

September 13th 2021, 7:43pm

IASLC World Conference on Lung Cancer

Neoadjuvant treatment with cisplatin/pemetrexed plus atezolizumab, followed by maintenance atezolizumab, demonstrated early efficacy with acceptable safety in patients with resectable pleural mesothelioma.

Yoga Possesses Potential to Improve QoL, Immune Responses, and Inflammation in Prostate Cancer

September 13th 2021, 7:24pm

American Urological Association Annual Meeting

Improvements in quality of life, antitumor immune responses, and inflammation could be resulting benefits of the incorporation of regular yoga practice in the lives of men with prostate cancer who are undergoing prostatectomy.

MRgFUS Improved Sexual Function, Urinary Continence in Men with Intermediate-Risk Prostate Cancer

September 13th 2021, 6:35pm

American Urological Association Annual Meeting

Magnetic resonance-guided focused ultrasound focal therapy delivered to the index lesion produced better outcomes for men with intermediate-risk prostate cancer compared with radical prostatectomy or radiation therapy.

18F-DCFPyL Could Become a Key Diagnostic Tool for Biochemical Recurrence in Prostate Cancer

September 13th 2021, 6:26pm

American Urological Association Annual Meeting

18F-DCFPyL, a PET prostate specific membrane antigen targeting agent, demonstrated statistically significant potential in detecting biochemical recurrence in men with prostate cancer.

Panvac Plus BCG Does Not Significantly Delay Recurrence in Advanced NMIBC

September 13th 2021, 6:17pm

American Urological Association Annual Meeting

The addition of a recombinant pox-viral vector vaccine Panvac™ to bacillus Calmette-Guérin did not significantly improve clinical outcomes for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Mobocertinib Elicits Antitumor Activity in EGFR Exon 20 Insertion+ NSCLC After Disease Control With EGFR TKIs

September 13th 2021, 4:27pm

IASLC World Conference on Lung Cancer

Mobocertinib was found to provide a meaningful clinical benefit with acceptable tolerability in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer who had previously achieved disease control of 6 months or longer with EGFR TKIs.

Mobocertinib Plus T-DM1 Elicits Preclinical Activity in HER2 Exon 20 Insertion+ Lung Cancer Models

September 13th 2021, 4:08pm

IASLC World Conference on Lung Cancer

Mobocertinib plus ado-trastuzumab emtansine demonstrated inhibitory effects in HER2 exon 20 insertion–mutated lung cancer cell lines.

Masitinib Plus Docetaxel Produces PFS Benefit in mCRPC With Low Metastatic Involvement

September 13th 2021, 3:55pm

American Urological Association Annual Meeting

The investigational small molecule masitinib plus docetaxel resulted in a statistically significant 21% reduction in the risk of progression or death compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels of 250 IU/mL or less.

Avelumab Plus BCG Induction Shows Favorable Tolerability in BCG-Unresponsive NMIBC

September 13th 2021, 2:51pm

American Urological Association Annual Meeting

The addition of avelumab to Bacillus Calmette-Guerin induction therapy appeared to be safe and well tolerated in patients with BCG-unresponsive non–muscle invasive bladder cancer.

Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials

September 13th 2021, 2:45pm

American Urological Association Annual Meeting

Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.

Olaparib/Pembrolizumab Combo Continues to Show Promising Activity in mCRPC

September 12th 2021, 7:41pm

American Urological Association Annual Meeting

The combination of olaparib and pembrolizumab continued to demonstrate antitumor activity in patients with metastatic castration-resistant prostate cancer who previously received docetaxel.